ArticleJournal of the Chinese Medical Association : JCMA2026
Multi-agent chemotherapy for refractory head and neck cancer.
Article in Journal of the Chinese Medical Association : JCMA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) generally carries a poor prognosis. Although immunotherapies have improved outcomes for patients with high programmed death-ligand 1 (PD-L1) expression, treatment options remain poorly defined for those with low PD-L1 expression or those refractory to the EXTREME regimen (platinum-based chemotherapy plus cetuximab). To address this gap, we retrospectively evaluated the efficacy of the MEMOCLUB regimen (methotrexate, epirubicin, mitomycin-C, Oncovin, cisplatin, leucovorin, 5-fluorouracil, and bleomycin) for the treatment of platinum-refractory R/M HNSCC.
methodsThis retrospective cohort study, conducted at Taipei Veterans General Hospital, Taiwan, assessed the efficacy and safety of the MEMOCLUB chemotherapy regimen, administered with or without cetuximab, for platinum-refractory R/M HNSCC between 2015 and 2022. The study measured objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) according to the Response Evaluation Criteria in Solid Tumors 1.1 criteria. Statistical analyses were performed using Kaplan-Meier survival curves, log-rank tests, and the Cox proportional hazards model for identifying prognostic factors.
resultsA total of 124 patients were enrolled. The median PFS was 2.9 months and OS was 5.3 months. The ORR was 10.5%, with a corresponding disease control rate of 27.4%. In both univariate and multivariate analyses, cetuximab coadministration emerged as a significant prognostic factor for improved OS. Subgroup analysis revealed that cetuximab-naive patients derived the greatest survival benefit from the addition of cetuximab to the MEMOCLUB regimen. Hematological effects were the most common adverse events, with anemia being the most frequent. No cases of grade 3 or higher mucositis were reported.
conclusionThe MEMOCLUB regimen is a feasible salvage therapy in refractory HNSCC, which demonstrates reasonable efficacy and tolerability. The addition of cetuximab significantly prolonged survival in cetuximab-naive patients, suggesting that its coadministration is an advantageous strategy for this specific subgroup of platinum-refractory R/M HNSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.